Logo do repositório
 
Publicação

Effectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network study

2025-10-03Artigo científico Acesso aberto
Ver registo simples
datacite.subject.fosCiências Médicas::Ciências da Saúde
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorHumphreys, James
dc.contributor.authorBlake, Alexandre
dc.contributor.authorNicolay, Nathalie
dc.contributor.authorBraeye, Toon
dc.contributor.authorVan Evercooren, Izaak
dc.contributor.authorHansen, Christian Holm
dc.contributor.authorMoustsen-Helms, Ida Rask
dc.contributor.authorSacco, Chiara
dc.contributor.authorMateo-Urdiales, Alberto
dc.contributor.authorCastilla, Jesús
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorMachado, Ausenda
dc.contributor.authorBrito, André
dc.contributor.authorLjung, Rickard
dc.contributor.authorPihlstrom, Nicklas
dc.contributor.authorMansiaux, Yohann
dc.contributor.authorMonge, Susana
dc.contributor.authorBacci, Sabrina
dc.contributor.authorNunes, Baltazar
dc.contributor.authorVEBIS-Lot 4 working group
dc.date.accessioned2026-01-29T12:32:21Z
dc.date.available2026-01-29T12:32:21Z
dc.date.issued2025-10-03
dc.descriptionVEBIS-Lot 4 working group: Joris Van Loenhout, Massimo Fabiani, Patricia Soares, Anthony Nardone, Esther Kissling.
dc.description.abstractWe estimated vaccine effectiveness (VE) of Omicron JN.1-adapted COVID-19 vaccines administered during the 2024 autumnal vaccination campaign against COVID-19 hospitalisation and death among eligible individuals aged ≥65 years. The study period was October 2024-January 2025. Using a common protocol across six EU/EEA study sites, we linked electronic health records to construct retrospective cohorts and applied Cox modelling to estimate VE via confounder-adjusted hazard ratios. The majority of vaccines administered during the study period were Omicron JN.1-adapted COVID-19 vaccines (99 %). VE against hospitalisation was 60 % (95 % Confidence Interval: 48-70 %) and against COVID-19-related death was 78 % (95 %CI: 64-87 %) among individuals aged 65-79 years; 58 % (95 %CI: 48-66 %) and 62 % (95 %CI: 32-79 %) among those aged ≥80 years. These results indicate high effectiveness in the initial months of the campaign. Continued monitoring is necessary to confirm these results, including estimates of VE in those with longer time since vaccination and during different variant predominance periods.
dc.description.sponsorshipEuropean Centre for Disease Prevention and Control (ECDC) implementing Framework Contract ECDC/2021/018 ‘Vaccine effectiveness and impact of COVID-19 vaccines through routinely collected exposure and outcome using health registries’ (RS/2022/DTS/24104).
dc.identifier.citationVaccine. 2025 Oct 3:64:127752. doi: 10.1016/j.vaccine.2025.127752. Epub 2025 Sep 19
dc.identifier.doi10.1016/j.vaccine.2025.127752
dc.identifier.issn0264-410X
dc.identifier.pmid40974735
dc.identifier.urihttp://hdl.handle.net/10400.18/10784
dc.language.isoeng
dc.peerreviewedyes
dc.publisherElsevier
dc.relation.hasversionhttps://www.sciencedirect.com/science/article/pii/S0264410X25010497?via%3Dihub
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCOVID-19
dc.subjectCohort Design
dc.subjectElectronic Health Records
dc.subjectHospitalisation
dc.subjectMulti-country Study
dc.subjectSARS-CoV-2
dc.subjectVaccine Effectiveness
dc.subjectVEBIS-Lot 4
dc.subjectEurope
dc.subjectCuidados de Saúde
dc.subjectInfecções Respiratórias
dc.titleEffectiveness of JN.1 monovalent COVID-19 vaccination in EU/EEA countries between October 2024 and January 2025: a VEBIS electronic health record network studypor
dc.typejournal article
dspace.entity.typePublication
oaire.citation.startPage127752
oaire.citation.titleVaccine
oaire.citation.volume64
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameMachado
person.familyNameBrito
person.givenNameAusenda
person.givenNameAndré
person.identifier.ciencia-id1217-6076-5D88
person.identifier.ciencia-idBB16-7711-7AE7
person.identifier.orcid0000-0002-1849-1499
relation.isAuthorOfPublication544ad266-0c22-4a50-9ebc-86acc08d6666
relation.isAuthorOfPublication746ac7b7-e570-4dda-93ad-a45eac09ff49
relation.isAuthorOfPublication.latestForDiscovery544ad266-0c22-4a50-9ebc-86acc08d6666

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Effectiveness of JN1 monovalent COVID-19 vaccination in EUEEA countries between October 2024 and January 2025_a VEBIS electronic health record network study.pdf
Tamanho:
550.98 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DEP - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais